SCHEMBL22685010

SCHEMBL22685010

CCCN(CCC)C(=O)C(C)[O]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.46
CA9 Q16790 4/20 0.46
CA2 P00918 3/20 0.46
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
TP53 P04637 1/20 0.39
CA1 P00915 3/20 0.39
TDP1 Q9NUW8 2/20 0.35
LMNA P02545 2/20 0.35
HSD17B10 Q99714 1/20 0.35
P2RX1 P51575 2/20 0.34
P2RX4 Q99571 2/20 0.34
P2RX3 P56373 1/20 0.34
MLYCD O95822 2/20 0.33
POLB P06746 1/20 0.33
APEX1 P27695 1/20 0.33
BCHE P06276 1/20 0.33
FDPS P14324 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7062593 0.86 CA1 (0.50) CA12CA9CA2TSHRALDH1A1
SCHEMBL7497247 0.83 CA12 (0.44) CA12CA9CA2TSHRMAPK1
SCHEMBL9462283 0.82 CA12 (0.48) CA12CA9CA2TSHRMAPK1
SCHEMBL20472201 0.80 CA12 (0.46) CA12CA9CA2TSHRMAPK1
SCHEMBL3898588 0.79 LMNA (0.40) CA12CA9CA2ALDH1A1CA1
SCHEMBL24406281 0.78 CA12 (0.44) CA12CA9CA2TSHRMAPK1
SCHEMBL6201950 0.78 CA12 (0.44) CA12CA9CA2TSHRMAPK1
SCHEMBL21065447 0.78 CA12 (0.44) CA12CA9CA2TSHRMAPK1
SCHEMBL9873959 0.78 CA12 (0.44) CA12CA9CA2TSHRMAPK1
SCHEMBL4588825 0.78 CA12 (0.44) CA12CA9CA2TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3741757-B1 DIHYDROINDOLIZINONE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2023-07-26 EP disclosed
US-11530211-B2 Dihydroindolizinone derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-12-20 US disclosed
EP-3998107-A1 METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES Tokyo Institute of Technology (JP) 2022-05-18 EP disclosed
US-20210053965-A1 DIHYDROINDOLIZINONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-02-25 US disclosed
WO-2021006268-A1 METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES 国立大学法人東京工業大学 2021-01-14 WO disclosed
EP-3741757-A1 DIHYDROINDOLIZINONE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2020-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530211-B2 Dihydroindolizinone derivative INSR, GPR119, IAPP CA12 3048/4885CA9 3523/4885CA2 1700/4885
US-20210053965-A1 DIHYDROINDOLIZINONE DERIVATIVE INSR, GPR119, IAPP CA12 3048/4885CA9 3523/4885CA2 1700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.